Article

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

2022-04-06

Abstract excerpt

<h4>Background</h4> Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2 by binding to a highly conserved epitope in the receptor binding domain. It retains activity against the Omicron BA.1 variant and is used to treat immunocompromised patients as they are at increased risk for a severe outcome of COVID-19. <h4>Methods</h4> We studied viral evolution in 47 immunocompromised patients infected with Omic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7201702-92c7-562a-8fba-e357e05d57b9
DOI: 10.1101/2022.04.06.22273503

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantDOI 10.1101/2022.04.06.22273503Read

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patientsSemantic proximity Read

Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient PatientsSemantic proximity Read

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 InfectionSemantic proximity Read

Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.Semantic proximity Read

Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodiesSemantic proximity Read

Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.Semantic proximity Read

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5Semantic proximity Read

Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving SotrovimabSemantic proximity Read

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5Semantic proximity Read

<i>In vitro</i> evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolateSemantic proximity Read